Compare places

Two or three clusters, read side by side across sectors, research, companies, capital, infrastructure, government designations and UKIZ relevance. There is no score and no ranking: British clusters are different from one another, not better or worse than one another.

Choose up to three clusters

Side by side

Dimension	Leeds & West YorkshireYorkshire and the Humber	CambridgeEast of England
Sectors	Life Sciences, Digital Technologies, Financial Technology Supporting: Artificial Intelligence, Advanced Manufacturing, Creative Industries	Life Sciences, Semiconductors, Engineering Biology, Artificial Intelligence Supporting: Quantum Technologies, Advanced Materials, AgriTech & FoodTech, Digital Technologies
Research	University of Leeds	University of Cambridge Wellcome Sanger Institute MRC Laboratory of Molecular Biology
Companies	Leeds health data and digital health cluster	Cambridge semiconductor and processor IP cluster
Infrastructure	Not recorded on the map. Health data infrastructure, teaching hospitals and university research facilities.	Babraham Research Campus Cambridge Science Park University and institute laboratories, genomics and biomedical campus facilities, and semiconductor design capability.
Capital	Financial services depth locally, but early-stage health technology capital remains limited.	Specialist deep tech and life science funds, university-linked funds, and corporate partners; strong at seed, thinner at growth stage relative to demand.
Government programmes	No place-based designation recorded.	No place-based designation recorded.
What exists	National health data organisations, medical technology, a large financial and professional services base and a research university with data and materials strength.	Extreme research density for its size: life sciences and genomics, semiconductor and processor IP, engineering biology and AI, with a mature spin-out culture and specialist investors who understand long timelines.
What's missing · UKIZ interpretation	A clear route for companies to work with health data at scale, and clinical adoption pathways that move faster than pilot projects.	Ownership retention. Discovery and early company formation work; the Series B onward stage frequently transfers ownership overseas. Laboratory and scale-up space, power and housing also constrain growth.
What could connect · UKIZ interpretation	Leeds health data capability connected to Manchester clinical research and to medical technology manufacturing, giving companies discovery, evidence and production in one region.	Cambridge discovery connected to UK manufacturing and biomanufacturing capacity, and to later-stage domestic capital, so that value created here is realised here rather than acquired out of the country.
UKIZ relevance	Health data at population scale is a national asset. The proposed Manchester mission and Leeds capability are complementary rather than competing.	Cambridge produces intellectual property at a rate few places match, and loses ownership of too much of it at Series B. The proposed Oxford–Cambridge zone concentrates on commercialisation and retention rather than on more discovery.
Last verified	15 August 2026	15 August 2026

Proposed by UKIZ · independent · not a government designation

Back to the map →Methodology →